As KRAS mutation is one of the key oncogene drivers linked to aggressiveness in various human malignancies—including lung, colorectal, and pancreas cancers 25, 26—it is plausible that mutated KRAS drives both metastasis and cachexia and, consequently, correlates with poor prognosis. This evidence concerns the gene KRAS and pancreatic neoplasm.